Evidence map›Paper›PMID 30631747›Full record

ArticleClinical cancer drugs2018

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.

Anna R Schreiber, Anna Nguyen, Stacey M Bagby, John J Arcaroli, Betelehem W Yacob, Kevin Quackenbush, Joe L Guy, Thomas Crowell, Bradley Stringer, Hadi Danaee and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Immunotherapy for precision medicine in colorectal cancer.Expert review of precision medicine and drug development · 2025
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Anna R SchreiberDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Anna NguyenDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Stacey M BagbyDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
John J ArcaroliDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Betelehem W YacobDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Kevin QuackenbushDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Joe L GuyUniveristy of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
Thomas CrowellTakeda, Cambridge, MA, USA.
Bradley StringerTakeda, Cambridge, MA, USA.
Hadi DanaeeTakeda, Cambridge, MA, USA.
Thea KalebicTakeda, Cambridge, MA, USA.
Wells A MessersmithDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Todd M PittsDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
University of Colorado Anschutz Medical Campus · USTakeda (United States) · USMichigan Center for Translational Pathology · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NCI NIH HHS P30 CA046934
6 · The paper itself

Abstract

backgroundAntibody-drug conjugates (ADCs) are an emerging technology consisting of an antibody, linker, and toxic agent, which have the potential to offer a targeted therapeutic approach. A novel target recently explored for the treatment of pancreatic cancer is guanylyl cyclase C (GCC). The objective of this study was to determine the anti-tumorigenic activity of TAK-264, an investigational ADC consisting of an antibody targeting GCC linked to a monomethyl auristatin E payload

methodsThe antiproliferative effects of TAK-264 assessed in a panel of eleven pancreatic cancer cell lines. Additionally, ten unique pancreatic ductal adenocarcinoma cancer patient-derived xenograft models were treated with TAK-264 and the efficacy was determined. Baseline levels of GCC were analyzed on PDX models and cell lines. Immunoblotting was performed to evaluate the effects of TAK-264 on downstream effectors.

resultsGCC protein expression was analyzed by immunoblotting in both normal and tumor tissue; marked increase in GCC expression was observed in tumor tissue. The

conclusionTAK-264 has shown suppression activity in pancreatic cancer cell lines and in pancreatic PDX models. These findings support further investigation of ADC targeting GCC.

Indexed as

antibody-drug conjugateGCCpancreatic cancerPDX modelsp-histone H3TAK-264

Identifiers

PMID30631747
PMCPMC6324574
OpenAlexW2804567887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.